Summary
Twenty-two pituitary adenomas were examined on the secretion of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) using a cell immunoblot assay, and discussed regarding an association between cavernous sinus invasion and the secretion of these proteins. The cell immunoblot assay, a kind of immunoblot procedure, is able to detect proteins at the single cell level and to detect the incidence of tumour cells secreting the target proteins in the total tumour cell population. The incidence of tumour cells secreting MMP-9 was significantly higher in invasive adenomas than in noninvasive ones. On the other hand, TIMP-1 secretion was not detected in any adenomas in this study. This result suggested that MMP-9 secretion, and especially the number of MMP-9-secreting cells, may be associated with cavernous sinus invasion of pituitary adenomas.
Similar content being viewed by others
References
Arita J, Kojima Y, Kimura F (1993) Measurement of the secretion of a small peptide at the single cell level by the cell immunoblot assay: thyroidectomy increases the number of substance P-secreting anterior pituitary cells. Endocrinology 132: 2682–2688
Ballin M, Goweg DE, Sinha CC, Thorgeirsson UP (1988) Ras oncogene mediated induction of a 92 kDa metalloproteinase: strong correlation with the malignant phenotype. Biochem Biophys Res Commun 154: 832–838
Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363
Coudwell WT, Weiss MH (1991) Strategies for the manaement of nonfunctioning pituitary adenomas. In: Cooper PR (ed) Contemporary diagnosis and management of pituitary adenomas. American Association of Neurological Surgeons, Illinois, pp 29–35
De Clerck YA, Shimada H, Gonzalez-Gomez I, Raffel C (1994) Tumor invasion in the central nervous system. J Neurooncol 18: 111–121
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Irnmunol 133: 1710–1715
Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler-Stevenson WG, Lala PK (1994) Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-β. Exp Cell Res 214: 93–99
Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P (1993) Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. Virchows Archiv A Pathol Anat 422: 61–66
Hsu DW, Hakim F, Biller BMK, Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753–761
Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136: 37–43
Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1996) Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138 (4): 390–395
Kawamoto K, Uozumi T, Arita K, Takechi A, Kawamoto H (1995) Secretion of growth hormone (GH)-releasing hormone by GH-producing pituitary adenoma assessed by cell immunoblot analysis. Endocrine J 42: 89–93
Key G, Becker MHG, Baron B, Duchrow M, Schlüter C, Flad HD, Gerdes J (1993) New Ki-67-equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68: 629–636
Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb Ki 67. Acta Neurochir (Wien) [Suppl] 53: 60–64
Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67: 803–806
Liotta LA, Steuer-Stevenson WG (1990) Metalloproteinases and cancer invasion. Cancer Biol 1: 99–106
Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzier JL, Thorgeisson UP (1992) Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 12: 168–184
Miller DC (1991) Histopathological evaluation of pituitary tumors: help for the clinician. In: Cooper PR (ed) Contemporary diagnosis and management of pituitary adenomas. American Association of Neurological Surgeons, Illinois, pp 37–45
Moll UM, Youngleib GL, Rosinski KB, Quigley JP (1990) Tumor promoter-stimulatedMr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 50: 6162–6170
Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y (1994) Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-l by human brain tumors. J Neurosurg 81: 69–77
Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL (1993) Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastases of rat 13762 NF mammary adenocarcinoma. Cancer Res 53: 5802–5807
Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R 81994) Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol 18: 129–138
Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65: 733–744
Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64: 402–407
Shibuya M, Saito F, Davis RL, Hoshino T (1992) Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase α monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol 84: 178–183
Stetler-Stevenson WG (1990) Type IV collagenase in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289–308
Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434–1441
Watanabe H, Nakamishi I, Yamashita K, Hayakawa T, Okada Y (1993) Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci 104: 991–999
Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145–2154
Yamagata S, Ito Y, Tanaka R, Shimazu S (1988) Gelatinases of metastatic cell lines of murine colonie carcinoma as detected by substrate gel electrophoresis. Biochem Biophys Res Commun 151: 158–162
Zucker S, Lysik RM, Zarrabi MH, Moll U (1993)Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140–146
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawamoto, H., Kawamoto, K., Mizoue, T. et al. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta neurochir 138, 1442–1448 (1996). https://doi.org/10.1007/BF01411124
Issue Date:
DOI: https://doi.org/10.1007/BF01411124